Categories
Tag: NHS
16 UK biotech companies you should know about
The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023, the UK biotech scene is now one of the most vibrant in Europe, laying the…
GLP-1 agonists: what’s the hype about?
Glucagon-like peptide 1 (GLP-1) agonists were on everybody’s mind at the recent JPM healthcare conference in the U.S. as it was one of the major highlights at the event. But all the hype around this class of drugs, which took off when Ozempic was given the go-ahead by the U.S….
Study To Measure Cell-Free DNA Capture Potential Of BioCaptis Device
BIOCAPTIVA Ltd. has begun an ex-vivo study to determine whether its BioCaptis device can isolate pleural fluid cell-free DNA (cfDNA) from exudative pleural fluid samples in sufficient quantities to improve pleural disease diagnosis. The study will involve a collaboration between BioCaptiva, University of the Highlands and Islands (UHI), and NHS Highland….
Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer
Identification of DRGs in PCa Figure 1a showed the flow chart of this study. To explore the role of DRGs in PCa, we analyzed the gene expression profiles of these 15 DRGs in PCa patients. As shown in Fig. 1b, for ACTN4, TLN1, IQGAP1, CD2AP, FLNA, MYH9, MYL6, and ACTB genes, the…
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON–(BUSINESS WIRE)– Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the…
Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation
Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13…
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher…
New personalized therapy improves survival for patients with CLL leukemia, phase 3 trial finds
Credit: Pixabay/CC0 Public Domain Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase 3 trial has found. The trial, by the University of Leeds, is published in the New England Journal of Medicine and has been presented at…
Use logistic regression to predict on multiclass probabilities using Kaggle’s cirrhosis dataset | by Tracyrenee | Dec, 2023
According to the NHS website, cirrhosis is scarring of the liver caused by continuous, long-term liver damage. Scar tissue replaces healthy tissue in the liver and prevents the liver from working properly. The damage caused by cirrhosis can’t be reversed and can eventually become so extensive that your liver stops…
Lecturer in Genomic Informatics job with UNIVERSITY OF SOUTHAMPTON
Human Genetics & Genomic Medicine Location: Southampton General Hospital Salary: £38,205 to £56,021 Full Time Permanent Closing Date: Friday 12 January 2024 Interview Date: To be confirmed Reference: 2547323AF The post This post will be in the Human Genetic and Genomic Medicine (HGGM) Group, within the School of…
A genomic mutational constraint map using variation in 76,156 human genomes
Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Siwei Chen, Laurent C. Francioli, Julia K. Goodrich, Ryan L. Collins, Masahiro Kanai, Qingbo Wang, Jessica Alföldi, Nicholas A. Watts, Christopher Vittal, Timothy Poterba, Michael W. Wilson, Yekaterina Tarasova, William Phu, Riley Grant, Mary T. Yohannes, Namrata Gupta, Irina M. Armean, Samantha M. Baxter, Sarah E. Calvo, Katherine R. Chao, Sinéad Chapman, Beryl B. Cummings, Phil Darnowsky, Patrick…
Genomics England hiring PhD Bioinformatics Intern in London, England, United Kingdom
Company DescriptionGenomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the causes of disease and develop new treatments – with patients and participants at the heart of it all. Our mission is to continue refining, scaling, and evolving our ability to…
Inferring compound heterozygosity from large-scale exome sequencing data
Department of Neurology, Hospital of the University of the Pennsylvania, Philadelphia, PA, USA Michael H. Guo Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Michael H. Guo, Laurent C. Francioli, Sarah L. Stenton, Julia K. Goodrich, Nicholas A. Watts, Moriel Singer-Berk, Emily Groopman, Philip W. Darnowsky, Matthew Solomonson, Samantha Baxter, Jessica Alföldi, Irina M….
CASGEVY becomes world’s first approved CRISPR-based therapy
Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.K. has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR…
Advances in personalised medicine, leave data processing behind
The buzz around personalised medicine has long been felt in the halls of academic centres and pharmaceutical labs, and most people with an interest in health or medicine are aware of its potential. Here, Evan Floden shares what it will take to shore up these exciting possibilities. According to the…
PhD Bioinformatics Intern Job in Greater London, Pharmaceuticals & Life Sciences Career, Intern/Graduate Jobs in Genomics England
Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the causes of disease and develop new treatments – with patients and participants at the heart of it all. Our mission is to continue refining, scaling, and evolving our…
Energy Jobline hiring Senior Bioinformatics Engineer in Cambridge, England, United Kingdom
Company DescriptionGenomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the causes of disease and develop new treatments – with patients and participants at the heart of it all. Our mission is to continue refining, scaling, and evolving our ability to…
Reactions to the UK’s Approval of a CRISPR Medicine
Last week, the UK’s MHRA conditionally approved the world’s first CRISPR-Cas9 therapy: Casgevy for sickle cell disease and transfusion dependent beta thalassemia. The therapy has been developed by Vertex and CRISPR Therapeutics. A decision in the US is not expected until December 8. It’s a remarkable moment for the CRISPR…
Current controversy in prenatal diagnosis: The use of cfDNA to screen for monogenic conditions in low risk populations is ready for clinical use
Review doi: 10.1002/pd.6469. Online ahead of print. Affiliations Expand Affiliations 1 University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA. 2 Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada. 3 Genetics and Genomic Medicine, UCL Institute of Child Health and…
Low-carbon salbutamol inhaler a step closer as phase three trials announced
A low-carbon salbutamol metered-dose inhaler (MDI) that could reduce greenhouse gas emissions from use of the inhaler by around 90% is to advance to phase 3 trials in the first half of 2024. If successful, the phase 3 trials will support regulatory submissions in 2025, its manufacturer GSK has said….
Fees 2024, Admissions, Top Colleges, Jobs & Salaries
PhD in Bioinformatics in UK is a research-based doctoral program which focuses on understanding complex biological data using software tools. PhD in Bioinformatics in UK is a 3-4 years full-time and 6-8 year part-time program, offered at various prestigious institutions. The eligibility criteria of the PhD in Bioinformatics in UK…
GLH Bioinformatics Lead at NHS in London
Professional Responsibilities Accountable for the day to day management and continuous improvement of the bioinformatics pipelines for data analysis and management of large datasets. Steer the development of bioinformatics systems and ensure systems across the consortium meet the technical requirements of the service, as well as any contractual obligations. Accountable…
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -November 17, 2023 at 09:16 am EST
BOSTON – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent…
United Kingdom MHRA authorised Vertex and CRISPR Therapeutics’s gene edited therapy for sickle cell disease and thalassemia – Pharma News
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced on Thursday that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). CASGEVY has…
U.K. Approves Vertex/CRISPR Tx’s Casgevy for Sickle Cell and Beta Thalassemia
Credit: CIPhotos / iStock / Getty Images Plus In a big first, Vertex Pharmaceuticals and CRISPR Therapeutics announced today that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for Casgevy (exagamglogene autotemcel [exa-cel]) for the treatment of sickle cell disease (SCD) and transfusion-dependent beta…
Vertex Pharmaceuticals’ Casgevy Wins U.K. Approval for Sickle Cell Disease
In a landmark announcement for the CRISPR field and the sickle cell disease (SCD) community, the U.K. authorities have granted approval to Casgevy, the CRISPR-Cas9 therapy formerly known as exa-cel developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The U.S. Food and Drug Administration (FDA) is expected to follow suit in…
gene therapy pioneer to biotech rebuff?
Once thought to be a frontrunner in gene therapy, uniQure’s fame may no longer be coveted, as the biotech looks to reorganize by slashing its workforce, in an attempt to stay afloat. But how did things go awry for the company that was once in its prime in the DNA…
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS…
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center – Awakn Life Sciences (OTC:AWKNF), Compass Pathways (NASDAQ:CMPS)
The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways CMPS for Treatment-Resistant Depression and Awakn Life Sciences AWKNF for Severe Alcohol Use Disorder (SAUD). Details On Trials Compass Pathways plc CMPS will initiate the UK arm of its Phase 3 program…
King’s College Unveils New Psychedelics Research Centre
The Centre for Mental Health Research and Innovation officially opened on 15 November 2023 to accelerate research into psychedelics and develop new models of care for mental health. The new Centre is part of a pioneering long-term strategic partnership between biotechnology company Compass Pathways, South London and Maudsley NHS Foundation…
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS…
Compass Pathways initiates UK component of global phase 3
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS…
State Secretary Addresses AI Fringe in Speech
Good morning. A big thank you to Milltown Partners, too, and everyone involved in the AI Fringe, for putting on such an exciting range of events…of course, not just here in London but right across the UK – in Oxford, Cambridge, Bristol, Edinburgh and beyond. AI has the potential to…
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib
. 2023 Sep;202(5):985-994. doi: 10.1111/bjh.18953. Epub 2023 Jun 25. Nina Prokoph 1 , Jamie D Matthews 1 , Ricky M Trigg 1 , Ivonne A Montes-Mojarro 2 , G A Amos Burke 3 , Falko Fend 2 , Olaf Merkel 4 , Lukas Kenner 4 5 6 7 , Birgit Geoerger 8 9 , Robert…
Bioinformatics Engineer by Genomics England in Cambridge Ref: 220521763
Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the causes of disease and develop new treatments – with patients and participants at the heart of it all. Our mission is to continue refining, scaling, and evolving our ability to…
Genomics England hiring Senior Bioinformatics Engineer in London, England, United Kingdom
Company DescriptionGenomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the causes of disease and develop new treatments – with patients and participants at the heart of it all. Our mission is to continue refining, scaling, and evolving our ability to…
Senior Bioinformatics Engineer by Genomics England in Cambridge Ref: 220521761
Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the causes of disease and develop new treatments – with patients and participants at the heart of it all. Our mission is to continue refining, scaling, and evolving our ability to…
Bioinformatics Specialist Job in Greater London, Government & Public Sector Career, Permanent Jobs in NHS Blood and Transplant
Job summary The Histocompatibility & Immunogenetics (H&I) function supports haematopoietic stem cell and solid organ transplant programmes for hospitals throughout England. It also provides transfusion, platelet and granulocyte immunology investigations and donor services for the British Bone Marrow Registry, NHS Cord Blood Bank and platelet supply chain. The H&I…
MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer
Oct 28 2023Reviewed by Lily Ramsey, LLM The conditional Marketing Authorization for Great Britain is based on the single-arm Phase 1/2 EPCORE NHL-1 trial data, which demonstrated a 62% (86/139) overall response rate and 39% (54/139) complete response rate in patients. However, further data are awaited from an ongoing phase…
WGS-Based and Consumer-Directed Newborn Screening Test Launched
Credit: Kemal Yildirim/Getty Images Fore Genomics has launched its FORESITE 360 whole genome sequencing (WGS) service, which provides a complete DNA map of newborns, infants, and children using an at-home collection kit. The company says FORESITE 360 reveals genetically linked and clinically manageable diseases a baby or child might have…
Job vacancy: Senior Bioinformatician, The Royal Marsden NHS Foundation Trust, Sutton
Job overview The Clinical Genomics department at the Royal Marsden comprises both translational research and diagnostic laboratories, the postholder would be integral in supporting both areas. An expert in clinical bioinformatics, the postholder will actively lead in development and validation of bioinformatics solutions whilst encouraging the development of more junior…
From innovation to impact: Harnessing Real-World data to generate Real-World insights that accelerate the impact of precision medicine in Breast Cancer Treatment
Breast cancer affects millions of people worldwide. In 2020, 2.3 million women were diagnosed with breast cancer globally (1). In the UK, it is the most common cancer among women, with over 55,000 new cases diagnosed each year (2). Around 0.5-1% of breast cancers occur in men (1). In the…
Bioinformatics Specialist
Job details Posting date: 24 October 2023 Salary: £43,742.00 to £50,056.00 per year Additional salary information: £43742.00 – £50056.00 a year Hours: Full time Closing date: 15 November 2023 Location: London, NW9 5BG Company: NHS Jobs Job type: Permanent Job reference: M0048-23-0640 Apply for this job Summary The Histocompatibility &…
Epcoritamab Receives UK Approval for R/R DLBCL After 2 Prior Lines of Therapy
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted conditional marketing authorization to epcoritamab-bysp (Tepkinly) monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after 2 or more systemic therapy.1,2 The decision was supported by data from the phase 1/2 EPCORE…
Novel injectable bispecific antibody for advanced lymphoma receives EU and UK green light
The injectable bispecific antibody epcoritamab (brand name Tepkinly) has been granted conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), its manufacturer Abbvie has announced. This follows its conditional marketing authorisation by the European Commission in late September 2023. The conditional marketing authorisations recommend epcoritamab as a…
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer
HENDERSON, Nev., Oct. 23, 2023 /PRNewswire/ —VolitionRX Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology. In early-stage…
As the UK’s AI Safety Summit Approaches, Governments Must Take Steps to Harness the Technology
Our recent past has been defined by ever-accelerating technological progress. Digital technologies have advanced rapidly, diffused across societies and ushered in a new era by providing the modern infrastructure required to collect data at scale. In the coming decades, artificial intelligence (AI) will have consequences that compare to the Industrial…
Global Genomics Market Research Report 2027: In-Depth Analysis
Genomics is a branch of biology that investigates an organism’s complete gene set or genome, focusing on DNA analysis. This comprehensive study involves understanding the gene structure, function, and their interactions within an organism. Genomic research often entails sequencing an organism’s DNA to identify and categorize all its genes. This…
Young mum told ‘it’s good to lose weight after having a baby’ before cancer diagnosis
A young mum from Weymouth was told ‘it’s good to lose weight after having a baby’ as she fought for a diagnosis that later turned out to be cancer. Ollie Louise Isbel was 22 when she had her daughter Harper last year and was told after her eventual diagnosis that she…
New NHS Treatment Offers Hope for Blood Cancer Patients
In a groundbreaking development, the UK’s National Health Service (NHS) is set to provide a potentially curative treatment for patients suffering from diffuse large B-cell lymphoma (DLBCL). This aggressive form of blood cancer has left many patients with limited options for treatment. However, the recent approval of the drug, Glofitamab,…
Patrycja Koziol joins Salus Wellness Clinics
Patrycja is a certified health coach specializing in healthy ageing, age reversing, and healing endometriosis naturally. She graduated from the College of Naturopathic Medicine in London and has NHS accreditation. Patrycja has also trained in a variety of other health modalities, including how the body works, nutrition, and fitness. Patrycja…
NICE recommends Roche’s Columvi for advanced lymphoma in UK
Around 700 people in the UK could benefit from the new treatment The National Institute for Care and Excellence (NICE) has recommended Roche’s Columvi (glofitamab) for NHS use as a treatment option for a type of blood cancer known as diffuse large B-cell lymphoma (DLBCL). Over 700…
Treatment for diffuse large b cell lymphoma to be made available on the NHS
Hundreds of people with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS. DLBCL is a type of non-Hodgkin lymphoma. The drug, which has the brand name Columvi® will be made available within weeks for…
In The Case Of Lymphoma, NICE Recommends Roche Biologics
(CTN News) – A drug used to treat advanced lymphoma has been recommended by the National Institute for Health and Care Excellence (NICE) as a new treatment option for patients with advanced lymphoma. Bispecific monoclonal antibodies (BsAbs) are indicated for the treatment of adults with relapsed or refractory diffuse large…
Newly-approved cancer drug to benefit patients within weeks, NHS suggests
Hundreds of NHS cancer patients are set to benefit from a potentially curative treatment thanks to a new recommendation from the National Institute for Health and Care Excellence (NICE). The new treatment comes in the form of glofitamab for an aggressive type of blood cancer called diffuse large B-cell lymphoma…
MHRA approves ‘potentially curative’ blood cancer treatment
Patients with an aggressive type of blood cancer are set to benefit from a ‘potentially curative’ new treatment option on the NHS. Glofitamab (Columvi) has been approved by the MHRA and recommended by NICE for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The treatment, which is administered intravenously,…
NICE recommends Roche biologic for lymphoma
Glofitamab is the first treatment to be recommended by the National Institute for Health and Care Excellence (NICE) at the same time as it is approved advanced lymphoma in the UK. In final guidance, the National Institute for Health and Care Excellence (NICE) has recommended glofitamab as a new treatment…
Genomics summit speaker calls for radical thinking to aid millions of rare disease patients
Hope is not lost for the thousands of individuals dealing with rare or undiagnosed diseases, urged Neil Ward, Vice President and General Manager EMEA for PacBio talking at the Genomics England Research Summit. In his presentation to the event, Ward outlined the scale of the issue, saying that undiagnosed rare…
Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer
Mice strains Six- to eight-week-old (age), 20–25-g (weight), both male and female (sex) mice were used for tumor xenografts generation and in vivo efficacy studies as described in the text (see Table 3). Athymic Nude (Envigo) Foxn1nu/Foxn1+ or NOD.Cg Prkdcscid Il2rgtm1Wjl/SzJ also called NSG mice were used. All animal procedures were…
Post-Expansion Biomolecule Profiling of the Digested and Expanded Tissue
To begin, take the digested and expanded archived or fresh clinical tissue sample and proceed with antibody staining by placing it in a single well of a six-well cell culture plate. Wash the sample three times with PBS for 10 minutes each at room temperature. Depending on the sample size,…
Mainstreaming whole genome sequencing: where are we now?
Genomic testing capabilities are advancing in affordability and accessibility by the day. But what is the current trajectory of whole genome sequencing in healthcare? As massively parallel sequencing, also known as next-generation sequencing, facilitates faster, cheaper access to the genome, genomic testing is touching more areas of healthcare than ever…
BIOCAPTIVA to conduct ex-vivo study to evaluate the potential of the BioCaptis device to capture cell free DNA to improve pleural disease diagnosis
BIOCAPTIVA to conduct ex-vivo study to evaluate the potential of the BioCaptis device to capture cell free DNA to improve pleural disease diagnosis Study aims to establish whether BioCaptis technology can be used to isolate cell free DNA (cfDNA) from pleural fluid samples in sufficient quantities for downstream DNA…
BIOCAPTIVA to conduct ex-vivo study to evaluate the
Study aims to establish whether BioCaptis technology can be used to isolate cell free DNA (cfDNA) from pleural fluid samples in sufficient quantities for downstream DNA analysis Goal is to identify tumour specific mutations to aid diagnosis of pleural disease and cancer type without requiring invasive biopsy Study to be…
International study reveals 11 new genes linked to aggressive prostate cancer
An international study has identified 11 new gene alterations connected to more aggressive prostate cancer using a simple blood test. The discovery could improve treatments for prostate cancer by better personalising treatment options for patients and spotting those most at risk of aggressive disease and disease progression. The study was…
Protein Expression Market to be Worth $5 Billion by 2030
According to a new market research report titled, Protein Expression Marketby System (Mammalian [CHO, HEK 293], Non-mammalian [Bacterial, Insect, Yeast]), Offering (Kits & Reagents, Vectors, Competent Cells, Services), Application (Industrial, Therapeutic, Research), and End User Global Forecast to 2030,published by Meticulous Research, the protein expression market is projected to reach…
What Is the Future for Multicancer Early Detection Tests?
PARIS — Multicancer early detection blood (MCED) tests are the focus of intensive development. What techniques do these tests use? What potential do they show? Suzette Delaloge, MD, MSc, oncologist, breast cancer specialist, and director of the individualized cancer prevention program (Interception) at the Gustave Roussy Institute in Villejuif, France,…
Genomics England Releases List of over 200 Rare Conditions for Newborn Screening Study
Credit: comzeal/Getty Images Genomics England has published an initial list of over 200 rare conditions that will be screened as a part of its new Generation Study, a program aimed at understanding whether sequencing babies’ genomes through newborn screening can help discover and treat rare genetic conditions earlier. The study will analyze the DNA…
Efficacy of radiotherapy in prostate cancer maintained with shorter dosing regimen
Stereotactic body radiation therapy (SBRT) delivered in fewer and higher doses over 5 sessions led to similar safety and efficacy outcomes in patients with intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy (EBRT) delivered in lower doses over several weeks, according to new data from the phase…
Should all newborns be offered DNA sequencing?
The human genome project cost $2.7 billion and took 13 years to read all 3 billion genetic letters in the human DNA code. But since then, the molecular biological revolution that has swept the globe means that this feat can now be achieved for less than a 3 figure sum…
Akari Therapeutics Reports First Half 2023 Financial Results And Highlights
(MENAFN– GlobeNewsWire – Nasdaq) Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA) Granted orphan drug designation from the European Commission for treatment in hematopoietic stem cell…
Research Fellow, Human Genetics & Genomic Medicine job with UNIVERSITY OF SOUTHAMPTON
Human Genetics & Genomic Medicine Location: Southampton General Hospital Salary: £38,205 to £41,732 per annum Full Time Fixed Term until 01/11/2026 Closing Date: Tuesday 24 October 2023 Interview Date: To be confirmed Reference: 2458823AF Applications are invited for a Research Fellow position based at Southampton General Hospital. This…
Many British health trusts slow to adopt electronic records systems, shows BMJ survey
Many health organizations in England are still reliant on paper patient notes and drug charts, despite progress toward electronic records and prescribing, The BMJ has found. The National Health Service (NHS) says it is investing nearly 2 billion pounds ($2.5 billion) to encourage trusts to adopt electronic patient records (EPRs)….
Protein Expression Market to be Worth $5 Billion by 2030 –
Redding, California, Sept. 21, 2023 (GLOBE NEWSWIRE) — According to a new market research report titled, ‘Protein Expression Market by System (Mammalian [CHO, HEK 293], Non-mammalian [Bacterial, Insect, Yeast]), Offering (Kits & Reagents, Vectors, Competent Cells, Services), Application (Industrial, Therapeutic, Research), and End User – Global Forecast to 2030,’ published…
Whole Genome Sequencing Market Revenue, Growth Rate, Report Analysis, Size, Share, With Forecast Overview 2023 to 2032 | CAGR of 20.6%
The latest report published by Report Ocean, titled “Whole Genome Sequencing Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023 to 2031,” offers a comprehensive assessment of the industry, including valuable insights into market trends. The report encompasses competitor and regional analysis, as well as the latest developments…
The next frontier in genomic technologies for rare diseases
By Neil Ward, VP and General Manager at PacBio EMEA It’s been 40 years since the passage of the Orphan Drug Act, which catalyzed the development of hundreds of therapies for rare diseases, with more than half approved in the last decade. More recently in 2022, the U.K. government launched…
Syphilis transmission networks and antimicrob
Scientists have used genomics to reveal distinct sexual networks for syphilis transmission, defined geographically or by sexual preference, among a background of wider circulation in England. They also show a presence of drug resistance in the majority of cases. By grouping closely related strains of the bacterium that causes syphilis…
expert reaction to Phase 3 study of MDMA therapy for moderate to severe PTSD
September 14, 2023 Results of a phase 3 trial looking at MDMA-assisted therapy for moderate to severe PTSD have been published in Nature Medicine. Dr James Rucker, Senior Clinical Lecturer in psychopharmacology and mood disorders at King’s College London, said: “This is the second phase 3 clinical trial of…
Bioinformatics Engineer by Genomics England in Cambridge, Cambridgeshire Ref: 220182846
Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the causes of disease and develop new treatments – with patients and participants at the heart of it all. Our mission is to continue refining, scaling, and evolving our ability to…
Wright’s staining for accurate diagnosis of leukemia
Introduction Leukemia, a generic term, encompasses several life threatening malignant disorders that present with incremental amounts of leucocytes in blood and bone marrow. Leukemia cells have the innate ability for migration and invasion.1 Dedifferentiated and malignant leucocytes not only retain the benign leucocytes capacity for cell motility and survival in…
“Selection and enumeration of low EpCAM expressing breast cancer CTCs u” by Brandy Charon Snowden
Abstract Breast cancer cells overexpress EpCAM that can be used as a marker to select breast cancer CTCs from heterogeneous clinical samples, even when present in low abundance. This study used MDA-MB-231 cells which have a low expression level of EpCAM (1.7 x 103 binding sites per cell.3) Herein, we…
BRAIN MATRIX study identifies barriers to fast brain tumour diagnosis
The Tessa Jowell BRAIN MATRIX study is pioneering the diagnosis of brain tumours. It focusses on gliomas – the most common primary brain tumour. The study aims to improve diagnosis by adding DNA sequencing into brain tumour diagnosis. It aims to test the possibility of using existing NHS infrastructure to…
Annual NHS flu vaccination program for children is getting underway
The annual NHS flu vaccination program for children aged 2 to 3 years, school age children and children over 6 months with certain health conditions is getting underway. Parents will receive invites from next week. The UK Health Security Agency (UKHSA) and NHS England are calling on parents to make…
A second update on mapping the human genetic architecture of COVID-19
Broad Institute of MIT and Harvard, Cambridge, MA, USA Masahiro Kanai, Christine Stevens, Benjamin M. Neale, Mark Daly, Andrea Ganna, Amy Trankiem, Mary K. Balaconis, Samuli Ripatti, Lindo Nkambul, Mark J. Daly, Sam Bryant & Matthew Solomonson University of California San Francisco, San Francisco, CA, USA Shea J. Andrews Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland Mattia Cordioli, Mark…
Research Fellow / Senior Research Fellow in Bioinformatics job with UNIVERSITY OF SOUTHAMPTON
Enterprise Units Location: Southampton General Hospital Salary: £34,980 to £56,021 Per annum Full Time Fixed Term (12 months) Closing Date: Tuesday 03 October 2023 Interview Date: To be confirmed Reference: 2428423CM The newly established Faculty of Medicine Bioinformatics Research Facility (Bio-R) serves as a centralised resource for providing…
Research Fellow / Senior Research Fellow in Bioinformatics at University of Southampton
Full Time Fixed Term (12 months) The newly established Faculty of Medicine Bioinformatics Research Facility (Bio-R) serves as a centralised resource for providing expert & timely bioinformatics consulting and data analysis solutions. The BIO-R’s mission is to build and maintain an infrastructure that provides the application of robust bioinformatics to enable…
Ovarian cancer research: five recent breakthroughs
With around 7500 new cases reported in the U.K. alone every year, ovarian cancer may occur because of the inheritance of faulty genes like BRCA. Although the exact reason for cancer-causing genetic mutations is unknown – as with all other kinds of cancer – ovarian cancer research has shown that…
Two Key Genes Revealed in Chemotherapy Resistance
Summary: Researchers identified two genes – NEK2 and INHBA – responsible for causing chemotherapy resistance in head and neck cancer patients. Remarkably, when these genes are silenced, previously resistant cancer cells begin responding to chemotherapy. From a chemical library, the team pinpointed two substances (Sirodesmin A and Carfilzomib) that can…
GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture
Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands Remi Stevelink, Dorothee Kasteleijn-Nolst Trenite, Bobby P. C. Koeleman, Dick Lindhout & Anja C. M. Sonsma School of Pharmacy and Biomolecular Sciences, The Royal College of Surgeons in Ireland, Dublin, Ireland Ciarán Campbell, Gianpiero L. Cavalleri, Norman Delanty, Hany El-Naggar, Austin Lacey & Peter Widdess-Walsh The FutureNeuro Research Centre, Dublin, Ireland…
Positive framing of genomics met with skepticism in some communities
Credit: Pixabay/CC0 Public Domain New research published in Human Genetics and Genomics Advances reveals the difference between “what we say” and “what people hear” when engaging underrepresented communities around genomics and health care. Genomics datasets, which underpin the ability to interpret all genetic tests, are known to consist of DNA…
Genpax Estimates Significant Cost Savings, Health Benefits From WGS Infection Surveillance
NEW YORK – Bioinformatics company Genpax estimates that healthcare systems can save considerable money while preventing infection outbreaks through microbial whole-genome sequencing. In a study published earlier this month in Microbial Genetics, the London-based company calculated that implementing a WGS surveillance strategy could prevent some 74,000 infections annually in England, saving…
siRNA therapy shows long-term potential in lowering LDL-C
New data presented at the European Society of Cardiology (ESC) Congress 2023, showed Novartis’ Leqvio® (inclisiran) provided an approximate 49 percent reduction in LDL cholesterol beyond six years of clinical observation. Novartis has announced that Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy indicated to reduce low-density…
Lymph Node Classification May Help Prognosticate in Esophageal Cancer
“Survival incrementally improved with better lymph node response (none/partial/complete). This was independent of the response in the primary tumor and the same survival benefit was observed in all stratified categories of N status,” according to Andrew Davies, MD. Evidence of pathological lymph node regression following neoadjuvant chemotherapy and surgical resection…
UK researchers develop new test for myeloid leukaemia cancers
The test involves patients giving a blood sample, which is used to extract DNA for limited sequencing. Credit Nguyễn Hiệp on Unsplash. Researchers from the Wellcome-MRC Cambridge Stem Cell Institute (CSCI), the University of Cambridge’s Department of Haematology and the Instituto de Investigación Sanitaria del Principado de Asturias (ISPA) have…
Whole genome sequencing could transform the management of health care-associated infections
Credit: CC0 Public Domain An economic model by bioinformatics company Genpax published in Microbial Genomics concludes that in England the National Health Service (NHS) could save close to £0.5bn and prevent 1,200 avoidable deaths, and the US health system over $3bn and 4,800 deaths by implementing whole genome sequencing (WGS)…
Genomics aids non-invasive prenatal diagnosis
Prenatal genetic diagnosis currently exists in the form of invasive procedures, which carry small risks of miscarriages. But technology in genomics is bringing significant change to the forefront. “Genomics has an influence on prenatal diagnosis in several ways. “For instance, we can now analyse cell free DNA in the mother’s blood, and because this contains foetal as well as…
Why measure soluble interleukin-2 receptor levels?
Sponsored Content by TecanAug 22 2023Reviewed by Olivia Frost The measurement of soluble interleukin-2 receptor (sIL-2R) levels in serum or plasma in adults has become a valuable tool for clinicians to assess immune function in vivo as part of the investigation, management, or prognosis of a wide range of diseases….
Plant-derived nanovesicles facilitate tumor therapy
Introduction Tumors are the second leading cause of death worldwide, with approximately 1670 deaths per day in the United States and 7700 deaths per day in China.1,2 The fundamental reason why cancers are still considered “frightening” is the difficulty of early tumor detection and the variety of issues present in…
Global genomic collaboration provides diagnos
image: An illustration showing flashing neurons. view more Credit: CREATED BY THE HOSPITAL FOR SICK CHILDREN (SICKKIDS) USING MIDJOURNEY Epilepsy in infants ranges in severity and can leave caregivers with questions about their child’s health. While genetic testing to help determine the cause of epilepsy is possible, comprehensive testing does not…
Our ultimate aim is to convert every diagnostic lab into a clinical genomics lab:Dr. Anirvan Chatterjee, HaystackAnalytics, ET HealthWorld
Shahid Akhter, editor, ETHealthworld, spoke to Dr. Anirvan Chatterjee, Co-founder & CEO, HaystackAnalytics, to figure out emerging trends in genome sequencing and how it can be made more affordable. Molecular Diagnostics MarketWhen we talk about how the market is moving in terms of the number of tests and the total…
‘Precision prescribing could save millions’ :: C+D
In 2022, the NHS spent £9.69 billion on prescribing drugs to patients in England. But ensuring these drugs are truly effective for patients remains a challenge for policy and health decision makers. In fact, 55% of adults are prescribed drugs that may be ineffective for them due to their genetic…